Bozhou Traditional Chinese Medicine Commodity Exchange Center, China's first "smart medicine market" innovatively created by ZBD, has officially opened. The project integrates the upstream and downstream industries of Chinese herbal medicine trading, forming an "Internet +" innovation ecosystem of Chinese herbal medicine industry
With high quality research and development as the core, ZBD actively promotes the adjustment and upgrading of product structure, and creates a product structure and layout that is based on traditional Chinese medicine products and covers multiple varieties, multiple dosage forms and multiple product specifications of chemical and biological drugs.
ZBD new-type big health industry pattern established. The company has formed a characteristic innovation and development layout with the support of "scientific and technological research and development, pharmaceutical industry, traditional Chinese medicine industry and financial investment". The goal of the enterprise is to build an international benchmark enterprise for the whole industrial chain of health industry.
Heilongjiang ZBD Pharmaceutical Co., Ltd. was listed on the Shanghai Stock Exchange and listed on the A-share main board. The stock abbreviation is "ZBD", the stock code is "603567". The enterprise has officially entered a new era of "product management + capital management".
Anhui Bozhou Herbal Medicine Company and Yunnan Panax notoginseng Planting Base have been put into use one after another, and ZBD has established the development pattern of health industry chain. And will "build a harmonious home on ZBD" as the enterprise's future development goal.
With the completion of the planning and design of the establishment of companies in Hulin, Harbin, Jixi, Bozhou and other places, ZBD has completed the transformation from the "multi-point and first-line" production layout to the new pattern of the development of the whole pharmaceutical industry chain, and extended to the direction of the big health industry.
With the establishment of Jixi Branch, the production and operation scale of ZBD has been further expanded, and the pharmaceutical industry system of "multi-point and front-line" has been completed. Group operation mode is opened inside the enterprise.
ZBD has established a strategic development layout that focuses on the development of "cerebrovascular" disease drugs, supplemented by all kinds of traditional Chinese medicine and chemical medicine products. It lays a solid foundation for the future development of ZBD.